Wu XW, Yang MF, Li N, Wang FY. Unfavorable outcome of antiviral therapy in cytomegalovirus-positive ulcerative colitis may be due to inappropriate study inclusion in meta-analysis. World J Gastroenterol 2015; 21(5): 1689-1690 [PMID: 25663793 DOI: 10.3748/wjg.v21.i5.1689]
Corresponding Author of This Article
Fang-Yu Wang, PhD, Department of Gastroenterology and Hepatology, Jinling Hospital, Medical School of Nanjing University, No. 305 Zhongshan East Road, Nanjing 210002, Jiangsu Province, China. wangfangyu2014@126.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letters To The Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Feb 7, 2015; 21(5): 1689-1690 Published online Feb 7, 2015. doi: 10.3748/wjg.v21.i5.1689
Unfavorable outcome of antiviral therapy in cytomegalovirus-positive ulcerative colitis may be due to inappropriate study inclusion in meta-analysis
Xiao-Wei Wu, Miao-Fang Yang, Nan Li, Fang-Yu Wang
Xiao-Wei Wu, Miao-Fang Yang, Nan Li, Fang-Yu Wang, Department of Gastroenterology and Hepatology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, China
Author contributions: Wu XW, Li N and Wang FY contributed to primary concept and data analysis; Wu XW and Yang MF contributed to writing the manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Fang-Yu Wang, PhD, Department of Gastroenterology and Hepatology, Jinling Hospital, Medical School of Nanjing University, No. 305 Zhongshan East Road, Nanjing 210002, Jiangsu Province, China. wangfangyu2014@126.com
Telephone: +86-25-80860051 Fax: +86-25-80860151
Received: September 9, 2014 Peer-review started: September 10, 2014 First decision: October 14, 2014 Revised: November 13, 2014 Accepted: December 16, 2014 Article in press: December 16, 2014 Published online: February 7, 2015
Abstract
Some previous articles reported that antiviral treatment was effective to reduce the colectomy rate in ulcerative colitis (UC) patients with cytomegalovirus (CMV) infection. Kopylov et al recently carried out a systematic review and meta-analysis to evaluate the impact of antiviral therapy on CMV-positive UC. The results showed that patients who received antiviral treatment had a higher risk of 30-d colectomy. We found that in this meta-analysis, some studies were inappropriately included, leading to an unfavorable outcome of anti-CMV therapy in UC patients.
Core tip: A recently article in the World Journal of Gastroenterology entitled “Antiviral therapy in cytomegalovirus-positive ulcerative colitis: A systematic review and meta-analysis” showed that antiviral therapy caused a higher risk of 30-d colectomy in cytomegalovirus-positive ulcerative colitis patients. We found that in this article, unfavorable outcome of antiviral therapy was due to inappropriate study inclusion in meta-analysis.
